Study design Randomized controlled trial. Objectives To determine the effect of zoledronic acid on bone loss in people with acute spinal cord injury (SCI) Settings Sawai Man Singh Medical College, India. Methods Sixty patients with acute SCI were randomized to receive either standard treatment alone or standard treatment with zoledronic acid within 3 months after injury. Areal bone mineral density (aBMD) was measured at the hip using dualenergy X-ray absorptiometry (DXA) at baseline 3, 6, and 12 months. Results Significant differences in aBMD were found between the standard treatment alone and standard treatment plus zoledronic acid group at the femoral neck (−0.13; 95% CI, −0.18 to −0.09, p < 0.0001), and total hip (−0.16; 95% CI, −0.19 to −0.12, p < 0.0001), respectively, at 1 year and bone loss was reduced in the zoledronic acid treated group as compared to the standard treatment group. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites. [Femoral neck −0.08; 95% CI, −0.12 to −0.03; p = 0.002 and total hip −0.12; 95% CI, −0.15 to −0.08; p < 0.0001] Conclusion A zoledronic acid 5 mg infusion given within 3 month significantly reduces bone loss at the hip after 6 months post infusion in patients with acute SCI.
Background: Low back pain (LBP) is a major health issue that causes more disability and global burden than any other conditions. It is one of the
most common musculoskeletal disorders. Chronic low back pain (CLBP) is dened as a pain that persists for more than 3 months, or longer than the
expected healing period. It is associated with increased medical expenditure, work absence, and loss of quality of life. This study aims to ascertain
efcacy of 5% dextrose (D5W) in chronic non-specic low back pain.
Material and Methods: This study is conducted on patient suffering from chronic low back pain presenting in Department of PM&R, SMS
Hospital, Jaipur. It is a Single blind randomized control trial study. We include 34 patients of non-specic chronic LBPin each group as sample size
which is further enhanced and rounded off to 40 patients in each group as nal sample size expecting 10% attrition/drop out.
Results: We found that mean age of our study group is 49 years. This is female dominant study with 56.25% patients. Dextrose participants
reported greater Numerical Rating scale pain score change at baseline (6.4 vs 6.25 points, p=0.59), but there is signicant reduction of mean NRS
st nd rd st pain score at 1 week (4.9 vs 5.4 points, p=01), 2 week (4 vs 5.45 points, p=0.0001), 3 week (3.15 vs 5.32 points, p=0.<0.0001), 1 month (2.95 vs
nd rd 5.32 points, p=<0.0001), 2 month (2.9 vs 5.32 points, p=<0.0001) and 3 month (2.82 vs 5.32 points, p=<0.0001).
CONCLUSION: Serial caudal epidural injection of D5W resulted in consistent post injection analgesia and clinically signicant improvement in
pain through 3 months among participants with non-specic CLBP. Patients with CLBPcan be treated effectively by using 5% dextrose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.